Shared escape mechanisms for both sorafenib and regorafenib have been speculated in HCC cells treated with IGF1 suggesting a key role for this factor in antagonizing drug-mediated growth, migration and invasion inhibition, as well as the drug-mediated induction of apoptosis. This evidence concerns the gene IGF1 and hepatocellular carcinoma.